Featured Company News – Haemonetics Announces FDA Clearance for its NexSys PCS; Set to Reduce Cost per Liter of Plasma Collected

Research Desk Line-up: C. R. Bard Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Haemonetics Corp. (NYSE: HAE), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HAE. The Company announced on July 28, 2017, that it has received FDA 510(k) clearance for its NexSys PCS plasmapheresis system. Haemonetics is a global health care Company which delivers a suite of hemotology products and solutions for the customers. The NexSys PCS includes bi-directional connectivity to Haemonetics’ donor management system, NexLynk DMS, and builds on Haemonetics’ industry leading position with a user-centric research-based design. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Medical Instruments & Supplies industry. Pro-TD has currently selected C. R. Bard, Inc. (NYSE: BCR) for due-diligence and potential coverage as the Company reported on its financial results for Q2 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on C. R. Bard when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HAE; also brushing on BCR. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=HAE

http://protraderdaily.com/optin/?symbol=BCR

The Announcement

The Company views this announcement as a step to expand its product range in its domestic market and improve quality and compliance in plasma collection centers. The open architecture of NexSys PCS facilitates bi-directional connectivity to donor management systems to help with the automated collection procedure programming and automated end of procedure documentation. The simple guided operation, intuitive touch screen, and on-screen troubleshooting assistance on this machine enhance the plasma center efficiencies resulting in reduced total time for donors in the center and greater collection capacity per plasma center.

NextSys PCS and NextLynk DMS were previously known as PCS 300 and NextGen DMS. On December 08, 2016, Haemonetics released an extensive upgrade to NextGen DMS (Donor Management System), an innovative software suite, where the core feature upgrades included reducing the cost per liter of plasma collected, enhanced quality and regulatory compliance, where the Company leveraged data to analyze and improve plasma center operations. The release of NextGen DMS 4 enabled the automated donor address verification, paperless intake, and annual medical assessment, where the device has extended capabilities of the donor floor mobile application to streamline phlebotomy documentation.

PCS, the Plasma Collection System

PCS is a premier plasma collection system with self-loading pumps, auto-priming, comprehensive messaging, advanced optical sensors, minimal alarms, and easy-to-read display. The system includes multiple safety features, including redundant air detectors, a donor line pressure monitor, low anticoagulant ratios, a fluid sensor, and an enclosed centrifuge. The system is also available for use with EXPRESS software, an intelligent algorithm that contributes to a reduction in overall donation time.

Company Growth Prospects

Haemonetics, being a health care-oriented firm, has aimed to achieve equilibrium for enhanced productivity across the Company’s corporate structure. It formed a Scientific Advisory Council on June 22, 2017, as a part of its broader innovation agenda, advancing its commitment to scientific and clinical excellence. The SAC, composed of 15 leading physician-scientists, would advise Haemonetics’s management and Board of Directors on key clinical and scientific issues. The SAC will also, as appropriate, deliver an opinion on strategic issues impacting product and clinical matters.

Haemonetics released its full-year FY17 results on May 08, 2017, where it reported a net operating loss of $19.4 million against $43.9 million loss in full-year FY16. The Company reported its FY18 guidance where in the plasma sector, it expects a growth of 3%-5% YOY; in the Hospital sector, a growth of 7%-10%; and a 7%-10% decline in the Blood Center sector. The Company also included the anticipated investments of $70 million to $90 million in FY18 guidance.

Last Close Stock Review

On Friday, July 28, 2017, the stock closed the trading session at $42.00, jumping 6.36% from its previous closing price of $39.49. A total volume of 988.12 thousand shares have exchanged hands, which was higher than the 3-month average volume of 305.91 thousand shares. Haemonetics’ stock price soared 0.29% in the last three months, 5.50% in the past six months, and 40.75% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 4.48%. At Friday’s closing price, the stock’s net capitalization stands at $2.07 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470060